BL-9020

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug NameBL-9020
Drug Alias NameNCR1.15natural killer receptor p46 inhibitors (Hebrew University of Jerusalem/ Ben-Gurion University Of The Negev/ BioLineRx)BL-9020JHL-1311EDP-10
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionNatural cytotoxicity triggering receptor 1 inhibitors
TargetsNatural cytotoxicity triggering receptor 1
Therapy Area/IndicationsDiabetes Mellitus, Type 1
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryTaiwanIsraelMainland China
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaPending
Originator CompaniesThe Hebrew University Of Jerusalem
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBiolinerx LtdHadasit Medical Research Services & Development LtdThe Hebrew University Of Jerusalem +[5] 
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 1

Other Information

ATC CodeN/A
Related LinksN/A